U.S. Physical Therapy (USPH) Q3 2026 earnings review
Hospital partnerships lift U.S. Physical Therapy profit, but medical claims bite
U.S. Physical Therapy's new hospital partnerships lifted clinic pricing and restarted profit growth after a flat first half. The operator of outpatient physical therapy clinics and workplace injury prevention programs completed converting 72 clinics into hospital alliances, lifting average revenue per visit by $5 to a record $111. Chief executive Chris Reading kept the full-year outlook unchanged, which by our math requires fourth-quarter EBITDA excluding one-offs to grow 17% at the middle of the range.
| Mature clinic sales growth | +6.4% +3.5% last quarter |
|---|---|
| Revenue | $223M +13% from a year ago |
| EBITDA, excluding one-offs | $27.8M +16% from a year ago |
| Full-year EBITDA outlook | Unchanged middle of the range: 9.5% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the hospital conversions finished on time, drove mature clinic sales up 6%, and proved that hospital billing rates lift profit. Workplace injury prevention sales from businesses owned a year ago also bounced back to 8% growth, easing concern over a lost automaker contract. One caution: high employee medical claims cut physical therapy margins by 1.5 percentage points and forced management to cut administrative staff.
The question now is whether hospital partnerships and Medicare rate increases will drive a lasting profit step-up in 2027, or whether rising employee medical bills and partner buyout costs will absorb the gains. If administrative cuts hold and hospital referrals grow, clinic margins will expand; if medical claims stay elevated, fourth-quarter profit will land near the bottom of the company's plan. Fourth-quarter results and the 2027 outlook in February will settle it.
🐂 Bull Case
Hospital Partnerships Lifted Clinic Pricing and Profit
U.S. Physical Therapy is converting clinics in New York and on the Gulf Coast into 10-year partnerships with local hospital systems. Under these agreements, the clinics bill under the hospitals' insurance contracts and receive staff cost reimbursements. By the end of September, the clinic operator finished converting all 72 contracted locations, up from 31 in the second quarter. Chief executive Chris Reading said the New York partnership is already performing "ahead of where we expected to be at this point".
- Hospital affiliation revenue: $25.0 million, up from $5.6 million last quarter, or 13.2% of physical therapy sales by our math
- Physical therapy revenue per visit: $110.61, up $5.07 from a year ago and reaching $112 in September
- Sales at clinics open over a year: up 6.4% from a year ago, compared with 3.5% growth last quarter
- Average daily visits per clinic: 33.4, up from 32.2 a year ago, extending a 27-month streak of monthly volume records
Because the hospital contracts pay more per visit than standalone clinic rates, this shift lifted overall clinic pricing by 4.8% and drove a 16.5% jump in EBITDA excluding one-offs, by our math. The fourth quarter will be the first period with all 72 clinics running under the hospital agreements for the full three months.
What to watch: hospital affiliation revenue in the fourth quarter and management's 2027 profit target for these partnerships, due in February. A fourth-quarter figure well above $25 million will confirm that the September additions in New York and the Gulf Coast are lifting the baseline into next year.
Workplace Injury Prevention Rebounded Without New Acquisitions
The company's industrial injury prevention unit, called IIP, provides onsite injury prevention, rehabilitation and employment testing inside large factories and warehouses. Sales growth at IIP businesses owned a year ago had slowed for three straight quarters, dropping from 18.4% in the second quarter of 2025 to 3.6% last quarter after a Japanese automaker ended a contract.
In the third quarter, total IIP revenue rose 13.8% to $33.0 million, and sales from businesses owned a year ago rebounded to 8.0% growth. Segment gross margin expanded by 2.3 percentage points from a year ago to 21.9%, as operating costs grew 10.5% while revenue grew 13.8%. That rebound eases concern that the unit was losing its growth momentum, though Reading cautioned that manufacturing clients typically shut down factories to retool at year-end, making the fourth quarter seasonally slow.
What to watch: underlying IIP revenue growth in the fourth quarter and the 2027 contract pipeline update in February. Holding mid-single-digit underlying growth through the winter factory shutdowns would show the unit has moved past the automaker contract loss.
Medicare Rules Turn Into a Multi-Year Tailwind
After five years of government payment cuts, Medicare reimbursement for physical therapy turned positive in 2026. Finance chief Nchacha Etta said Medicare revenue per visit rose 2% from a year ago in the third quarter, beating management's 1% estimate, while workers' compensation revenue per visit jumped 8% and commercial insurance rates were flat.
In November, federal regulators released the final 2027 Medicare payment rule. On an early read, Reading estimates the rule will lift base therapy rates by about 0.7% next year. More importantly, regulators agreed to phase out an individual practice cost index modifier, known as IPSI, over two years starting in 2027. That formula had penalized outpatient clinics that do not use expensive surgical gear, so removing it will lift the company's reimbursement rates for several years.
What to watch: management's exact dollar calculation of the 2027 Medicare rate update and the IPSI phase-out, which Reading promised to share once his team finishes mapping regional rates. A multi-million-dollar annual lift would add pure profit because clinic staffing costs are already covered.
🐻 Bear Case
Employee Medical Claims Keep Squeezing Clinic Margins
"Cost pressures from our self-insured employee medical program continued in Q3," chief executive Chris Reading said. Because the company pays its workers' medical bills directly up to a stop-loss limit, a small number of complex hospital cases — including several premature infants — pushed employee health claims $7 million higher than last year over the first nine months and $2 million over budget in the third quarter alone.
Those insurance bills cut physical therapy gross margin by about 1.5 percentage points in the quarter. While the press release text claimed physical therapy gross margin excluding one-offs rose 1.5 percentage points, the reconciliation table and finance chief Nchacha Etta confirmed it rose only 0.6 percentage points, from 18.5% to 19.1%. Salaries and related costs stayed flat at 58.2% of segment revenue, and rent, supplies and contract labor rose 0.3 percentage points of total revenue to 18.6%.
To offset the medical bills, management made "targeted labor reductions" across clinic front desks and cut discretionary spending in mid-October. East Coast operations chief Eric Williams said the company removed "several million dollars worth of labor". Even so, Reading warned that medical claims may stay hot in the fourth quarter, when the full-year outlook requires EBITDA excluding one-offs to grow 17% at the middle of the range, by our math.
What to watch: fourth-quarter physical therapy gross margin and salaries as a share of revenue. If medical claims eat up the autumn administrative staff cuts and the full-quarter hospital rate lift, full-year profit will land near the bottom of the $102 million to $106 million plan.
Partner Buyout Accounting Drove a Reported Loss
U.S. Physical Therapy acquires majority stakes in clinics while local therapist partners keep minority stakes that they can later sell back to the company. Under accounting rules, when clinic profits rise, Those partner stakes become more valuable, and the jump in value is deducted when calculating profit per share. As Etta noted, "stronger operating results are contributing to the GAAP loss per share."
- Reported loss per share: $1.04, compared with $0.48 of earnings a year ago and $0.80 excluding one-offs
- Partner stake revaluation charge to retained earnings: $36.2 million ($26.6 million after tax) in the third quarter, up from $7.9 million a year ago
- Redeemable partner stakes on the balance sheet: $357.3 million, up 21.8% from $293.3 million at year-end 2025 by our math
- Credit facility debt: $247 million, up 52.5% from $162 million at year-end 2025, pushing quarterly interest expense up 48.8% to $3.6 million
While the per-share charge is an accounting adjustment, the $357.3 million balance-sheet liability represents real future cash buyouts as partners retire or exercise their options. Over the first nine months, the healthcare group spent $22.6 million buying out minority partner stakes and $13.6 million paying contingent earn-outs, funded in part by borrowing more on its credit lines.
What to watch: cash spent on minority partner buyouts in the fourth quarter and 2027, particularly as the New York partnership's higher profits make its 50% partner stake more expensive to buy.
💲 Other KPIs
Corporate overhead fell 0.8 percentage points of revenue from 8.8% a year ago, and dropped from 9.2% in the first quarter and 8.9% in the second. Excluding one-off software upgrade and acquisition costs, corporate expenses fell from 8.5% of revenue to 7.7%, helping offset higher clinic medical benefit costs.
By our math, cash generated after capital spending rose 32.2% from $15.6 million a year ago, equal to 9.3% of quarterly revenue. Over the first nine months, operating cash flow climbed 27.5% to $63.9 million on faster patient bill collections, easily covering $15.8 million of clinic equipment spending and $20.7 million of common dividends.
The share count fell 1.8% from 15.20 million a year ago and declined from 15.07 million in the second quarter. The clinic operator spent $19.2 million buying back 306,256 shares in the second quarter, nearly exhausting its $25 million buyback plan, and did not repurchase shares in the third quarter.
🔮 Guidance
Unchanged. Management kept its full-year target for EBITDA excluding one-offs for a third straight quarter, pointing to 9.5% growth at the middle of the range. With $75.0 million earned through September, the plan leaves $27.0 million to $31.0 million for the fourth quarter by our math, or 17.3% growth at the middle of the range. Full-quarter hospital partnership rates support that step-up, though seasonal factory shutdowns and employee medical claims remain headwinds.
❓ Key Questions
How much profit did the 72 hospital clinics add?
Hospital affiliation revenue jumped to $25.0 million in the third quarter, but management declined to say how much EBITDA those 72 clinics generated. Investors need to know how much the new partnerships are beating the original $7.3 million annual profit estimate.
How much will clinic administrative cuts save in 2027?
Operations chief Eric Williams said the company cut "several million dollars worth of labor" across clinic front desks and billing offices to offset high employee medical claims. Management has not given an exact annual savings figure or said how much fell into the third quarter.
What is the dollar lift from the 2027 Medicare rule?
Regulators finalized a ~0.7% base therapy rate increase for 2027 and a two-year phase-out of the penalizing IPSI cost modifier. Management needs to quantify the annual revenue and profit benefit once its regional rate review is complete.
What cash calls are coming from partner stake buyouts?
Redeemable partner stakes on the balance sheet climbed 22% this year to $357.3 million as partnership profits rose, while credit facility debt reached $247 million. Investors need visibility into how many partners plan to exercise their buyout options over the next year.